Shares of Achillion Pharmaceuticals, Inc. (ACHN) are up almost 8% to $7.93 in pre-market trading Monday. The spike may be attributed to an upgrade to ‘Overweight’ from ‘Neutral’ and a $10.00 from $5.00 price target at Piper Jaffray, which represents expected upside of 35.86% to the stock’s previous closing price of $7.36.
From a sentiment standpoint, ACHN, which was also upgraded to ‘Outperform’ from ‘Market Perform’ at Wells Fargo (WFC) this morning, has a number of analysts already in the bullish camp, as the biotech company boasts 2 “Strong Buys”, 4 ‘Buys’, 5 ‘Holds’ and not a single “Sell.”
On valuation-measures, shares of Achillion Pharmaceuticals have a P/E to growth ratio of -1.91 and a t-12 negative return on equity of -37.97%. EPS is at -$0.65. The company has a market cap of $712 million and a median Wall Street price target of $11.00 with a high target of $22.00. Achillion last announced its earnings results on August 7th, reporting a Q2’14 net loss of $15.7 million compared with a net loss of $19.9 million during the same period of FY2013.
ACHN has a beta of 1.80 and a short float of 35.20%. In the past 52 weeks, shares of Achillion Pharmaceuticals have traded between a low of $2.26 and a high of $8.61. The pharma company reported $140 million in cash vs. $256.000 in debt in its most recent quarter. ACHN is currently printing a one year return of about 15% and a year-to-date return of around 121.75%.
The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.
Achillion Pharmaceuticals, Inc., develops and commercializes anti-infective drug therapies in the U. S. and internationally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.